https://scholars.lib.ntu.edu.tw/handle/123456789/526556
標題: | Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome – Randomized, double-blind, phase III PHILO study | 作者: | Goto S. CHIEN-HUA HUANG Park S.-J. Emanuelsson H. Kimura T. |
公開日期: | 2015 | 卷: | 79 | 期: | 11 | 起(迄)頁: | 2452-2460 | 來源出版物: | Circulation Journal | 摘要: | Background: Few data on the relative efficacy and safety of new P2Y12 inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist. Methods and Results: The multicenter, double-blind, randomized PHILO trial compared the safety and efficacy of ticagrelor vs. clopidogrel in 801 patients with ACS (Japanese, n=721; Taiwanese, n=35; South Korean, n=44; unknown ethnicity, n=1). All were planned to undergo percutaneous coronary intervention and randomized within 24 h of symptom onset. Primary safety and efficacy endpoints were time to first occurrence of any major bleeding event and to any event from the composite of myocardial infarction, stroke or death from vascular causes, respectively. At 12 months, overall major bleeding occurred in 10.3% of ticagrelor-treated patients and in 6.8% of clopidogrel- treated patients (hazard ratio (HR), 1.54; 95% confidence interval (CI): 0.94–2.53); the composite primary efficacy endpoint occurred in 9.0% and in 6.3% of ticagrelor- and clopidogrel-treated patients, respectively (HR, 1.47; 95% CI: 0.88–2.44). For both analyses, the difference between groups was not statistically significant. Conclusions: In ACS patients from Japan, Taiwan and South Korea, event rates of primary safety and efficacy endpoints were higher, albeit not significantly, in ticagrelor-treated patients compared with clopidogrel-treated patients. This observation could be explained by the small sample size, imbalance in clinical characteristics and low number of events in the PHILO population. ? 2015, Japanese Circulation Society. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/526556 | ISSN: | 1346-9843 | DOI: | 10.1253/circj.CJ-15-0112 | SDG/關鍵字: | acetylsalicylic acid; clopidogrel; ticagrelor; ticlopidine; troponin I; adenosine; antithrombocytic agent; clopidogrel; ticagrelor; ticlopidine; acute coronary syndrome; adult; aged; Article; bleeding; bradycardia; controlled study; double blind procedure; drug efficacy; drug safety; drug withdrawal; dyspnea; female; follow up; heart ventricle extrasystole; human; loading drug dose; major clinical study; male; multicenter study; percutaneous coronary intervention; pharmacodynamics; phase 3 clinical trial; randomized controlled trial; ST segment depression; ST segment elevation; acute coronary syndrome; adverse effects; analogs and derivatives; Asian continental ancestry group; bleeding; blood; blood clotting parameters; chemically induced; clinical trial; comparative study; ethnology; Japan; middle aged; mortality; Myocardial Infarction; percutaneous coronary intervention; risk factor; South Korea; Stroke; Taiwan; time factor; treatment outcome; Acute Coronary Syndrome; Adenosine; Aged; Asian Continental Ancestry Group; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticlopidine; Time Factors; Treatment Outcome |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。